EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PO063 | EVALUATION OF PLATELET ACTIVATION MARKERS IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA

Marialaura Di Fuorti

Bleeding, Thrombosis and Vascular Biology · 26.10.2026 · 5 (s3)

DOI: 10.4081/btvb.2026.879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 26.10.2026. Verfasst von Marialaura Di Fuorti. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims. Thrombotic Thrombocytopenic Purpura (TTP) is a rare disease characterized by deficiency of ADAMTS13, a metalloprotease involved in the cleavage of high-molecular-weight (HMW) multimers of von Willebrand factor (VWF). This process regulates the interaction between VWF and platelet (PLT) membrane receptors, thereby supporting PLT adhesion to the sub endothelium and aggregation. In the onset and progression of TTP, the interaction between VWF and PLT plays a pivotal role. It is known that PLT glycoproteins (Gp), including GpIbα, GpIIb/IIIa, and GpVI, as well as the contents of alpha and dense granules and the ability of PLT to degranulate, contribute to PLT plug formation. In some conditions, these mechanisms may be overexpressed, leading to the development of thrombotic events. In this study, we aimed to investigate the contribution of PLT to the onset of TTP.Methods. Six patients with acquired TTP associated with the presence of anti-ADAMTS13 antibodies (Abs) were enrolled at the IRCCS CRO of Aviano. Two patients were evaluated during the disease acute phase, while the others during routine follow-up. The diagnostic work-up included assessment of ADAMTS13 activity, anti-ADAMTS13 Abs, VWF levels, and VWF multimer analysis. PLT activation markers were studied using an indirect method at the IRCCS Humanitas Research Hospital. Briefly, two whole-blood samples from healthy donors (HDs) were treated with 1 µM prostaglandin E1 and centrifuged twice at low speed to obtain a PLT pellet. One PLT sample was resuspended in plasma derived from TTP patients (PLT-TTP), while the other in plasma from HDs (PLT-HD), used as an autologous control. We investigated the expression of PLT GpIbα, GpIIb/IIIa, GpVI, P-selectin, PAC-1, mepacrine, and CD63 at steady state and after activation with the agonists ADP 10µM, collagen 5µg/mL, and TRAP 50µM. We also assessed VWF binding to PLT (VWF-PLT) after stimulation with ristocetin, by flow cytometry. Results were analyzed using descriptive statistics, reporting mean values, SEM, and p-values (p

Zitieren

APA

Fuorti, M. D. (2026). PO063 | EVALUATION OF PLATELET ACTIVATION MARKERS IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA. Bleeding, Thrombosis and Vascular Biology, 5(s3). https://doi.org/10.4081/btvb.2026.879

Vancouver

Fuorti MD. PO063 | EVALUATION OF PLATELET ACTIVATION MARKERS IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA. Bleeding, Thrombosis and Vascular Biology. 2026;5(s3). doi:10.4081/btvb.2026.879

BibTeX
@article{Fuorti2026,
  author = {Fuorti, Marialaura Di},
  title = {PO063 | EVALUATION OF PLATELET ACTIVATION MARKERS IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  volume = {5},
  number = {s3},
  doi = {10.4081/btvb.2026.879}
}
Kostenlos starten →